Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Psychosocial considerations in pediatric autoimmune liver disease
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Reply
Manuel Mendizabal, Nicolás Ducasa, Paula Benencio, Mirna Biglione, Ezequiel Mauro – 9 October 2022
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
Dawei Ding, Guanya Guo, Yansheng Liu, Linhua Zheng, Gui Jia, Juan Deng, Ruiqing Sun, Xiufang Wang, Changcun Guo, Yulong Shang, Ying Han – 9 October 2022 – Fenofibrate (FF) has shown potential benefits in patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid (UDCA). However, the efficacy and safety of FF in patients with cirrhosis remain unclear.
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
Anahita Rabiee, Yanhong Deng, Maria Ciarleglio, Jean L. Chan, Monica Pons, Joan Genesca, Guadalupe Garcia‐Tsao – 9 October 2022 – Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg, identifies patients with compensated cirrhosis at a high risk of decompensation. However, HVPG is an invasive and nuanced method.
Posttransplant considerations in autoimmune liver disease: Recurrence of disease and de novo
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases
Akiko Eguchi, Motoh Iwasa, Ryosuke Sugimoto, Mina Tempaku, Kyoko Yoshikawa, Naohiko Yoshizawa, Davide Povero, Kazushi Sugimoto, Hiroshi Hasegawa, Yoshiyuki Takei, Hayato Nakagawa – 4 October 2022 – Complement complex 1 subunit q (C1q) has multiple functions, including cell migration, in addition to its traditional complement‐activating effect. Research shows C1q is a ligand for frizzled receptors (FZDs).
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis
Xiaolin Wang, Seung‐Jin Kim, Yukun Guan, Richard Parker, Robim M. Rodrigues, Dechun Feng, Shelly C. Lu, Bin Gao – 4 October 2022 – Adipose tissue dysfunction is closely associated with the development and progression of nonalcoholic fatty liver disease (NAFLD). Recent studies have implied an important role of prohibitin‐1 (PHB1) in adipose tissue function. In the current study, we aimed to explore the function of adipocyte PHB1 in the development and progression of NAFLD.
Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice
Jie Jiang, Yuandi Ma, Yameng Liu, Dasheng Lu, Xiaoxia Gao, Kristopher W. Krausz, Dhimant Desai, Shantu G. Amin, Andrew D. Patterson, Frank J. Gonzalez, Cen Xie – 4 October 2022 – Nonalcoholic steatohepatitis (NASH) is a rapidly developing pathology around the world, with limited treatment options available. Some farnesoid X receptor (FXR) agonists have been applied in clinical trials for NASH, but side effects such as pruritus and low‐density lipoprotein elevation have been reported. Intestinal FXR is recognized as a promising therapeutic target for metabolic diseases.